Clinical Trial Update: Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 trial update for DX-88 evaluating efficacy and safety in treating acute attacks of hereditary angioedema (HAE) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DX-88

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2010-05-11